// App-Quantinova.ai

TPS9106 : A phase 2 study of poziotinib in patients with EGFR or HER2 exon 20 mutation-positive non-small cell lung cancer.

Researchers

Presenter

  • Zandong Yang

Principal Investigators

  • Nishan Tchekmedyian

  • David T. Chu

  • Guru Reddy

  • Gajanan Bhat

  • Mark A. Socinski

Medical Centers

  • Inovio Pharmaceuticals, Plymouth Meeting, PA

  • Pacific Shores Medical Group, Huntington Beach, CA

  • Stony Brook University, Stony Brook, NY

  • Spectrum Pharmaceuticals, Irvine, CA

  • Florida Hospital Cancer Institute, Orlando, FL

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Epidermal growth factor receptor

  • erb-b2 receptor tyrosine kinase 2

  • Threonine at amino acid position 790

Drug/Treatment

  • Poziotinib

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved